Zobrazeno 1 - 10
of 30
pro vyhledávání: '"June, Zhao"'
Autor:
Faiez Zannad, Bang‐Gee Hsu, Yoshitaka Maeda, Sug Kyun Shin, Elena M. Vishneva, Martin Rensfeldt, Stefan Eklund, June Zhao
Publikováno v:
ESC Heart Failure, Vol 7, Iss 1, Pp 55-65 (2020)
Abstract Aims Sodium zirconium cyclosilicate (SZC, formerly ZS‐9) is a selective K+ binder to treat adults with hyperkalaemia. HARMONIZE‐Global examined the efficacy and safety of SZC among outpatients with hyperkalaemia from diverse geographic a
Externí odkaz:
https://doaj.org/article/22079e569a2a48988684c8027b89cb44
Autor:
Annas, George J., Avila, Eli N., Avila, Eli N., II, Barker, Ellen, Ciammaichella, Ellia, DeVille, Kenneth A., DeVille, Michelle C., Fanaroff, Jonathan M., H. Firestone, Marvin, Griffin, Frank, Hall, John K., Hinnant, C. William, Johnston, James C., Kalen, Chemanthi, Kelly, Richard J., Lee, Henry C., Loue, Sana, M. O’Dell, Josanne (Jan), Paterick, Timothy E., D. Piorkowski, Joseph, S. Quang, Tony, Raskin, Michael M., Sanbar, Shafeek Sandy, Sanders, Mark A., P. Sartwelle, Thomas, Selkin, Stuart, Tovino, Stacey A., Turbow, Robert, Vinluan, Michael, H. Wecht, Cyril, (June) Zhao, Junying
Publikováno v:
In Legal Medicine Edition: Eighth Edition. 2025:vii-x
Publikováno v:
Clinical Pharmacology in Drug Development. 11:348-357
Sodium zirconium cyclosilicate (SZC) is an effective potassium binder for patients with hyperkalemia. This single-center, open-label, phase I study (NCT03283267) characterized the pharmacodynamics and safety of SZC in Chinese individuals. Twenty-two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c438a75b60d99e710caf486b7a7b2b1
https://doi.org/10.1002/cpdd.1055
https://doi.org/10.1002/cpdd.1055
Autor:
Takeshi Osonoi, Hiromasa Harada, Yoshimitsu Yamasaki, June Zhao, Hyosung Kim, Yugo Shibagaki, Toshitaka Yajima, Nobuaki Sarai, Naoki Kashihara
Publikováno v:
Clinical and Experimental Nephrology
Background Hyperkalemia is associated with many chronic diseases and renin-angiotensin-aldosterone system inhibitor therapy. Sodium zirconium cyclosilicate (SZC), an oral, highly selective cation-exchanger, is approved for the treatment of hyperkalem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23b6ce545983edb825d1f496d7d547ac
http://europepmc.org/articles/PMC7880936
http://europepmc.org/articles/PMC7880936
Autor:
Edgar V. Lerma, Javed Butler, Steven Fishbane, Bruce Spinowitz, June Zhao, David K. Packham, Stephan von Haehling, Peter A. McCullough, Philip T. Lavin, Mikhail Kosiborod, Simon D. Roger
Publikováno v:
Nephrology Dialysis Transplantation
Background Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is a selective potassium (K+) binder for the treatment of adults with hyperkalaemia. This post hoc analysis of an open-label, single-arm trial (NCT02163499) compared SZC efficacy and safe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::212945ac02a643da6a2207f541d0f2c6
https://doi.org/10.1093/ndt/gfz285
https://doi.org/10.1093/ndt/gfz285
Autor:
June Zhao, Edgar V. Lerma, Steven Fishbane, Simon D. Roger, Bhupinder Singh, Pablo E. Pergola, Bruce Spinowitz, Julian G. Martins, Philip T. Lavin, Mikhail Kosiborod, David K. Packham
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims Most patients with severe hyperkalaemia are treated in hospital settings and are often receiving renin–angiotensin–aldosterone system inhibitors (RAASi) and/or have chronic kidney disease. Sodium zirconium cyclosilicate (SZC;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cad168e4a9b6eb659726ce52eb6d86b0
https://doi.org/10.1093/ndt/gfaa142.p0189
https://doi.org/10.1093/ndt/gfaa142.p0189
Autor:
June Zhao, Bang‐Gee Hsu, Yoshitaka Maeda, Faiez Zannad, Martin Rensfeldt, Elena M. Vishneva, Stefan Eklund, Sug Kyun Shin
Publikováno v:
ESC Heart Failure
ESC Heart Failure, Wiley, 2020, 7 (1), pp.55-65. ⟨10.1002/ehf2.12561⟩
ESC Heart Failure, Vol 7, Iss 1, Pp 55-65 (2020)
ESC Heart Failure, 2020, 7 (1), pp.55-65. ⟨10.1002/ehf2.12561⟩
ESC Heart Failure, Wiley, 2020, 7 (1), pp.55-65. ⟨10.1002/ehf2.12561⟩
ESC Heart Failure, Vol 7, Iss 1, Pp 55-65 (2020)
ESC Heart Failure, 2020, 7 (1), pp.55-65. ⟨10.1002/ehf2.12561⟩
International audience; Aims: Sodium zirconium cyclosilicate (SZC, formerly ZS-9) is a selective K+ binder to treat adults with hyperkalaemia. HARMONIZE-Global examined the efficacy and safety of SZC among outpatients with hyperkalaemia from diverse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43924a2b6046e8a420840affa97f5b69
https://hal.univ-lorraine.fr/hal-02611239/file/ehf2.12561.pdf
https://hal.univ-lorraine.fr/hal-02611239/file/ehf2.12561.pdf
Autor:
Yiming Li, Jianhua Ma, Jae Hyeon Kim, Agata Ptaszynska, Wenying Yang, June Zhao, Zhiguang Zhou, Yanbing Li
Publikováno v:
Journal of Diabetes. 10:589-599
BACKGROUND This 24-week Phase 3 double-blind placebo-controlled study assessed the safety and efficacy of dapagliflozin as add-on to insulin, with or without oral antihyperglycemic drugs (OADs), in Asian patients with inadequately controlled type 2 d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d289e2229d77bae194d9d287138a875c
https://doi.org/10.1111/1753-0407.12634
https://doi.org/10.1111/1753-0407.12634
Autor:
Stephan von Haehling, Pablo E. Pergola, Steven Fishbane, June Zhao, Bhupinder Singh, Bruce Spinowitz, Javed Butler, Peter A. McCullough, David K. Packham, Scott Adler, Philip T. Lavin, Mikhail Kosiborod, Simon D. Roger, Edgar V. Lerma
Publikováno v:
Clin J Am Soc Nephrol
BACKGROUND AND OBJECTIVES: Oral sodium zirconium cyclosilicate (formerly ZS-9) binds and removes potassium via the gastrointestinal tract. Sodium zirconium cyclosilicate–associated restoration and maintenance of normokalemia and adverse events were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e9efe224b70347bcd4fa04d1dff59ae
https://europepmc.org/articles/PMC6556727/
https://europepmc.org/articles/PMC6556727/
Publikováno v:
Journal of Biological Chemistry. 291:18222-18231
Humans can incorporate the xenoglycan N-glycolylneuraminic acid (Neu5Gc) from the diet into reproductive tissues and secretions. Most humans also have circulating antibodies specific for this dietary xenoglycan. The potential for inflammation induced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::804f1ae2dfaa807405965b75aea2547b
https://doi.org/10.1074/jbc.m116.739169
https://doi.org/10.1074/jbc.m116.739169